FAQs

 

 

Q?

What is hair cloning

A.

Hair Cloning has been proposed for many years as the ultimate treatment for hair loss. Hair transplantation successfully moves hairs from one region of the scalp to balding regions but is not able to increase the total number of hairs available. Hair cloning would in effect, disassemble a few hair follicles, multiply these cells in the laboratory and then reintroduce them into the scalp to both rejuvenate miniaturising hair follicles and induce brand new hairs. Other groups have tried this but it has been found that when human follicle cells are cultured, they rapidly lose their functionality. Recent scientific breakthroughs however indicate how culture multiplication systems could be developed which is why we have created HairClone Inc. now.

Q?

What is cryopreservation

A.

Cryopreservation is a process where biological constructs are preserved by cooling to very low temperatures (typically -80 °C or -196 °C using). Cryopreservation methods seek to reach low temperatures without causing additional damage caused by the formation of ice during freezing. At low enough temperatures, any chemical activity in the cells is effectively stopped and at these low temperatures cells can be stored for many years and if thawed correctly are then able to function normally.

Q?

What are dermal papilla cells?

A.

Dermal papilla (DP) cells are mesenchymal cells that reside in the dermal papillae of the hair follicle. They are  the focus of intense interest because the DP not only regulates hair follicle development and growth, but is also thought to be a reservoir of multi-potent stem cells.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115771/

Q?

What is the hair follicle dermal papilla?

A.

The dermal papilla of the hair follicle follicle is a small “stud” of the dermis around which the mainly tubular indentation of the epidermis fits.  It is this tubular indentation that forms the hair follicle.

Q?

What is scientific innovation

A.

Scientific innovation develops potential new therapies, often in isolation in the laboratory. The first time clinicians and patients are involved in any significant way is at the later stages of development during the clinical trial phase and by then the potential product is “fixed” and the link with the scientists is broken.  This means that clinical trials often fail, not because the product doesn’t work, but because the trial design was incorrect. The wrong patient group was tested or the wrong procedure was used to provide the product to the patient.  This is much more critical with products that use surgery of some form or another as it is the correct  combination of product and surgery that is needed.  Unfortunately, when this is the case, the investment funds are not available to learn from the trial and start again.  This has been the case with hair cloning and it has resulted in several companies trying to develop hair cloning and then moving out of the field entirely.

Q?

What is medical innovation

A.

Medical innovation involves clinicians and surgeons using their skill and best judgement to develop a therapy.  With this process, different procedures are tried and communicated to colleagues and there is the steady evolution of best practice.  This is indeed exactly how hair transplantation developed from plug grafts, to strip grafts to follicular unit extractions.

Q?

When will Hair Cloning be available

A.

This is the question that we are asked most frequently and it is very difficult to answer.  To try to answer it, we have broken down what we need to do below and we will provide a more detailed explanation of this process as we develop the website.

Firstly, HairClone will need to research the optimum ways to multiply follicle cells in culture while still maintaining their activity and also the best way to return these cells to the scalp. The speed at which we can do this scientific parts of the research will depend on the amount of financial support that we receive through our various initiatives (see funding section).  The clinical aspects will depend on getting permissions from the various UK regulatory agencies and we are hoping that we can begin clinical experience on a small scale in the UK, in the second half of 2017.  At the same time, we can begin to cryopreserve and bank patients’ follicles. The revenue from this will be used to further support the research and clinical development and the patients who have banked follicles will have priority in regards to having treatments made available when we are ready to do so.

We hope that we can begin clinical trials proper within 3-5 years.  It will take time to complete these trials and then apply for and obtain marketing licences from the regulatory bodies before this becomes a routine clinical treatment around the world.  The management of HairClone, when in previous positions, have carried out over 19 different clinical trials around the world and have developed a variety of cell therapies that have treated around a million people so we have a huge amount of experience in this area.  We will do our utmost with the financial resources that we have to develop this therapy as quickly and efficiently as possible, but we will carry out each step ethically, with patient safety our top priority.  Please keep checking the website and follow us on Facebook (#HairClone) and Twitter (@HairClone) to keep updated on our progress.